News

Dr Schleicher, Dr Dickson Discuss New Roles at Tennessee Oncology

Watch the video HERE. Stephen Schleicher, MD, MBA, and Natalie Dickson, MD, discuss their new roles as chief medical officer (CMO) and chief strategy officer (CSO), respectively, at Tennessee Oncology. Tennessee Oncology announced new leadership roles for medical oncologist Stephen Schleicher, MD, MBA, and Natalie Dickson, MD, a medical oncologist/hematologist who most recently served as […]

Read More

Tennessee Oncology Appoints Dr. Stephen Schleicher as Chief Medical Officer and Promotes Dr. Natalie Dickson to President and Chief Strategy Officer

Nashville, Tennessee – January 3, 2022 – Tennessee Oncology, one of the largest providers of oncology care in the country, announced today that Stephen Schleicher, MD, MBA has been appointed Chief Medical Officer (CMO) effective January 1, 2022. Natalie Dickson, MD, President and CMO, will remain in her role as president of the company while […]

Read More

Tennessee Oncology Re-Certified With Perfect Score for High-Quality Cancer Care from the Largest Oncology Association in United States

Tennessee Oncology has received re-certification by the QOPI® Certification Program, LLC, a wholly owned subsidiary of the Association for Clinical Oncology (the Association) and an affiliate of the American Society of Clinical Oncology (the Society). The QOPI® Certification Program builds on the Society’s Quality Oncology Practice Initiative (QOPI®), providing a three-year certification for outpatient hematology-oncology […]

Read More

Provision Cares Proton Therapy Nashville Achieves Accreditation From World’s Leading Radiation Oncology Society

Provision CARES Proton Therapy Nashville has been accredited by the American Society for Radiation Oncology (ASTRO) through APEx – Accreditation Program for Excellence®. This achievement means cancer patients in Middle Tennessee not only have access to one of the world’s most advanced cancer treatments, but can also rest assured knowing their care will be of […]

Read More

H3 Biomedicine Presents Investigational Data Update on H3B-6545 for Treatment of Locally Advanced or Metastatic Estrogen Receptor- positive, HER2-negative Breast Cancer at San Antonio Breast Cancer Symposium

H3 Biomedicine Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the presentation of two posters at the 2021 San Antonio Breast Cancer Symposium (SABCS) being held in a hybrid format on December 7- 10, 2021. The presentations include interim investigational data from H3’s ongoing clinical development program, […]

Read More